OpenAI Acquires Orchestra Bio, AI Agents Take Over Drug Discovery

OpenAI has officially announced its acquisition of Orchestra Bio, a San Francisco–based startup focused on developing AI agents for the pharmaceutical industry to track drug development progress in real time. Orchestra’s entire team and technology platform will be integrated into Rosalind, OpenAI’s life sciences product line tailored for biologists and chemists. The financial terms of the deal were not disclosed. Founded in the fall of 2022, Orchestra raised approximately $20 million in seed funding from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC. According to OpenAI, bringing a new drug to market—from initial concept to final U.S. regulatory approval—can take up to 15 years, with total costs for a single approved drug often exceeding